Drug Farm Completes $55 Million First Tranche of Series D Financing

36Kr learned that Drug Farm today announced the completion of the first tranche of its $55 million Series D financing. This round of financing is jointly led by Shanghai Pudong Leading Zone Investment Center and Shanghai Puxing Coordination Private Equity Fund Partnership, with participation from Zhikai Capital Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Investment Partnership, and Keyuan Pharmaceutical. Existing investors including BioVeda China Fund, YD Capital, Jiashan State-owned Investment, DT Capital, Weidu Capital, and Biometas continue to participate in this round. Hyde Capital acted as the exclusive financial advisor for this transaction. The proceeds from the financing will be used to continuously advance the company's clinical and pre-clinical R&D pipelines, accelerate global clinical development projects, strengthen regulatory registration efforts in major markets, and further expand the company's R&D capabilities.